These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 2565233)

  • 41. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.
    McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG
    Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.
    Lammers JW; Müller ME; Folgering HT; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of xamoterol on peripheral blood vessels in healthy subjects.
    Fitzgerald DE
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):70S-72S. PubMed ID: 2572259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of the autonomic control of the failing heart.
    Snow HM
    Basic Res Cardiol; 1989; 84 Suppl 1():163-76. PubMed ID: 2573339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
    Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T
    Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 51. Acute and chronic effects of xamoterol in idiopathic dilated cardiomyopathy.
    Watanabe K; Hirokawa Y; Suzuki K; Shibata A
    Jpn Heart J; 1988 Sep; 29(5):603-15. PubMed ID: 2975712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.
    Sorensen EV; Faergeman O; Day M; Bastain W
    Eur J Clin Pharmacol; 1988; 35(2):183-5. PubMed ID: 2903827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of xamoterol, a partial beta 1-selective agonist, on physical performance capacity and cardiocirculatory, metabolic and hormonal parameters.
    Kullmer T; Kindermann W; Urhausen A; Hess M
    Eur J Clin Pharmacol; 1988; 34(3):255-62. PubMed ID: 2899509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of xamoterol in failing human myocardium.
    Schwinger RH; Böhm M; Erdmann E
    Eur Heart J; 1990 Apr; 11(4):323-7. PubMed ID: 1970536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in exercise tolerance and resting haemodynamics during long-term treatment of heart failure with xamoterol.
    Kayanakis JG; Courtault L; Fauvel JM; Boundhoure JP; Snow HM
    Eur Heart J; 1990 Apr; 11 Suppl A():52-3. PubMed ID: 2140552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of long-term xamoterol in idiopathic dilated cardiomyopathy.
    Watanabe K; Hirokawa Y; Suzuki K; Masani F; Otsuka H; Shibata A
    Jpn Circ J; 1992 Jan; 56(1):12-20. PubMed ID: 1347090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myocardial energetics in dilated cardiomyopathy.
    Thierfelder L; Holubarsch CH; Hasenfuss G; Just HJ
    Clin Cardiol; 1990 Sep; 13(9):649-54. PubMed ID: 1976466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.